Cost of microvascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil

References

• International Diabetes Federation. IDF diabetes Atlas Brussels, Belgium; 2019 [cited 2021 Feb]. Available from: https://www.diabetesatlas.org
   Google Scholar
• NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530.
   PubMed Web of Science ®Google Scholar
• Chen S, Kuhn M, Prettner K, et al. The macroeconomic burden of noncommunicable diseases in the United States: estimates and projections. PLOS One. 2018;13(11):e0206702.
   PubMed Web of Science ®Google Scholar
• Hayes A, Arima H, Woodward M, et al. Changes in quality of life associated with complications of diabetes: results from the ADVANCE study. Value Health. 2016;19(1):36–41.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928.
   PubMed Web of Science ®Google Scholar
• Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–2646.
   PubMed Web of Science ®Google Scholar
• Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149.
   PubMed Web of Science ®Google Scholar
• Chapman D, Foxcroft R, Dale-Harris L, et al. Insights for care: the healthcare utilisation and cost impact of managing type 2 diabetes-associated microvascular complications. Diabetes Ther. 2019;10(2):575–585.
   PubMed Web of Science ®Google Scholar
• Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–862.
   PubMed Web of Science ®Google Scholar
• Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health. 2018;21(7):881–890.
   PubMed Web of Science ®Google Scholar
• Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–2502.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S151–S167.
   PubMed Web of Science ®Google Scholar
• Barrett EJ, Liu Z, Khamaisi M, et al. Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab. 2017;102(12):4343–4410.
   PubMed Web of Science ®Google Scholar
• Lachin JM, Genuth S, Cleary P, et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381–389.
   PubMed Web of Science ®Google Scholar
• Julian GS, Campos D, Broe Honore J, et al. Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil. J Med Econ. 2020;23(9):985–993.
   PubMed Web of Science ®Google Scholar
• Ali MS, Ichihara MY, Lopes LC, et al. Administrative data linkage in Brazil: potentials for health technology assessment. Front Pharmacol. 2019;10:984.
   PubMed Web of Science ®Google Scholar
• The Commonwealth Fund. Brazil; 2020 [cited 2021 Feb]. Available from: https://www.commonwealthfund.org/international-health-policy-center/countries/brazil#:∼:text=Approximately%2075%20percent%20of%20Brazilian%20citizens%20rely%20solely%20on%20SUS
   Google Scholar
• Sistema Único de Saúde Department of Informatics. DATASUS [cited 2021 Feb]. Available from: https://datasus.saude.gov.br/
   Google Scholar
• Conselho Nacional de Saúde. Resolução No 510, de 07 de Abril de 2016; 2016 [cited 2021 Feb]. Available from: http://conselho.saude.gov.br/resolucoes/2016/reso510.pdf
   Google Scholar
• Campos DF, Rosim RP, Duva AS, et al. Brazilian healthcare record linkage (brhc-rlk) – a record linkage methodology for Brazilian medical claims datasets (DATASUS). Value Health. 2017;20:A321.
   Google Scholar
• Jacobs MS, van Leent MWJ, Tieleman RG, et al. Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands. J Med Econ. 2017;20(12):1231–1236.
   PubMed Web of Science ®Google Scholar
• DataSUS. The SUS table of procedures, medications and orthoses, prostheses and special materials (OPM) (SIGTAP); 2019 [cited 2021 Feb]. Available from: http://www.sgc.goias.gov.br/upload/links/arq_961_tabelacompleta.pdf
   Google Scholar
• Banco Central do Brasil. Câmbio e Capitais internacionais; 2019 [cited 2021 Feb]. Available from: https://www.bcb.gov.br/estabilidadefinanceira/historicocotacoes
   Google Scholar
• Nichols GA, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care. 2011;34(11):2374–2378.
   PubMed Web of Science ®Google Scholar
• Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications. 2004;18(1):18–26.
   PubMed Web of Science ®Google Scholar
• Chen D, Liu S, Tan X, et al. Assessment of hospital length of stay and direct costs of type 2 diabetes in Hubei province, China. BMC Health Serv Res. 2017;17(1):199.
   PubMed Web of Science ®Google Scholar
• Bahia LR, Araujo DV, Schaan BD, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health. 2011;14(5 Suppl 1):S137–S140.
   PubMed Web of Science ®Google Scholar
• Williams R, CODE-2 Advisory Board, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia. 2002;45(7):S13–S17.
   Web of Science ®Google Scholar
• Bahia LR, da Rosa MQM, Araujo DV, et al. Economic burden of diabetes in Brazil in 2014. Diabetol Metab Syndr. 2019;11:54.
   PubMed Web of Science ®Google Scholar
• Chen HY, Kuo S, Su PF, et al. Health care costs associated with macrovascular, microvascular, and metabolic complications of type 2 diabetes across time: estimates from a population-based cohort of more than 0.8 million individuals with up to 15 years of follow-up. Diabetes Care. 2020;43(8):1732–1740.
   PubMed Web of Science ®Google Scholar
• Abdi A, Jalilian M, Sarbarzeh PA, et al. Diabetes and COVID-19: a systematic review on the current evidences. Diabetes Res Clin Pract. 2020;166:108347.
   PubMed Web of Science ®Google Scholar
• Pal R, Bhadada SK. COVID-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes Metab Syndr. 2020;14(4):513–517.
   PubMed Web of Science ®Google Scholar
• Roncon L, Zuin M, Rigatelli G, et al. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 4. Lifestyle management. Diabetes Care. 2017;40(Suppl 1):S33–S43.
   PubMedGoogle Scholar
• Nascimento R, Álvares J, Guerra AAJ, et al. Availability of essential medicines in primary health care of the Brazilian unified health system. Rev Saude Publica. 2017;51(suppl 2):10s.
   PubMedGoogle Scholar
• Rocha WH, Teodoro J, Assis Acurcio F, et al. Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. J Comp Eff Res. 2021;10(6):519–532.
   PubMed Web of Science ®Google Scholar
• Barbosa MM, Nascimento RC, Garcia MM, et al. Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. J Comp Eff Res. 2021;10(3):243–253.
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–1224.
   PubMed Web of Science ®Google Scholar